T A B L E O F C O N T E N
and the children's study compared Oxis Turbohaler to Serevent Accuhaler. There was only one death in an adult (which was unrelated to asthma) and none in children, and there were no significant differences in non-fatal serious adverse events comparing formoterol to salmeterol in adults (Peto odds ratio (OR) 0.77; 95% confidence interval (CI) 0.46 to 1.28), or children (Peto OR 0.95; 95% CI 0.06 to 15.33). Over a six-month period, in studies involving adults that contributed to this analysis, the percentages with serious adverse events were 5.1% for formoterol and 6.4% for salmeterol; and over a three-month period the percentages of children with serious adverse events were 1.3% for formoterol and 1.3% for salmeterol.
Authors' conclusions
We identified four studies comparing regular formoterol to regular salmeterol (without randomised inhaled corticosteroids, but all participants were on regular background inhaled corticosteroids). The events were infrequent and consequently too few patients have been studied to allow any firm conclusions to be drawn about the relative safety of formoterol and salmeterol. Asthma-related serious adverse events were rare and there were no reported asthma-related deaths.
P L A I N L A N G U A G E S U M M A R Y

Regular treatment with formoterol versus regular treatment with salmeterol in chronic asthma: serious adverse events
Asthma is a common condition that affects the airways -the small tubes that carry air in and out of the lungs. When a person with asthma comes into contact with an irritant (an asthma trigger), the muscles around the walls of the airways tighten, the airways become narrower, and the lining of the airways becomes inflamed and starts to swell. This leads to the symptoms of asthma -wheezing, coughing and difficulty in breathing. They can lead to an asthma attack or exacerbation. People can have underlying inflammation in their lungs and sticky mucus or phlegm may build up, which can further narrow the airways. There is no cure for asthma; however there are medications that allow most people to control their asthma so they can get on with daily life.
Long-acting beta 2 -agonists, such as formoterol and salmeterol, work by reversing the narrowing of the airways that occurs during an asthma attack. These drugs -taken by inhaler -are known to improve lung function, symptoms, quality of life and reduce the number of asthma attacks. However, there are concerns about the safety of long-acting beta 2 -agonists, particularly in people who are not taking inhaled corticosteroids to control the underlying inflammation.
We did this review to take a closer look at the safety of people taking formoterol daily compared to salmeterol daily. All participants were prescribed regular background treatment with inhaled corticosteroids. We found three trials on 1116 adults and one trial on 156 children. There was not enough information to draw any conclusions on the relative safety of regular formoterol and regular salmeterol in chronic asthma, but serious asthma-related events were rare, and only one non-asthma-related death was reported. No deaths were related to asthma. Risks were calculated from pooled risk differences However, there is also longstanding controversy over the regular use of beta 2 -agonists in asthma. Sears 1986 suggested that excessive use of short-acting beta 2 -agonists might have contributed directly or indirectly to increases in asthma deaths in New Zealand between 1960 and 1980. The authors commented that "most deaths were associated with poor assessment, underestimation of severity and inappropriate treatment (over-reliance on bronchodilators and under use of systemic corticosteroids), and delays in obtaining help."
Concern remains that the symptomatic benefit from treatment with long-acting beta 2 -agonists might lead to underestimation of attack severity in acute asthma, and could lead to an increase in asthma-related deaths (as seen in SMART 2006). Furthermore, regular treatment with beta 2 -agonists can lead to tolerance to their bronchodilator effects and this phenomenon may be more marked with longer-acting as opposed to shorter-acting compounds (Lipworth 1997). A number of molecular mechanisms have been proposed to explain the possible detrimental effect of long-term beta 2 -agonist use in asthma, including desensitisation due to receptor down regulation with cellular internalisation (Giembycz 2006) .
A recent systematic review of the effect of long-acting beta 2 -agonists on severe asthma exacerbations and asthma-related deaths (Salpeter 2006) concluded that "long-acting beta-agonists have been shown to increase severe and life-threatening asthma exacerbations, as well as asthma-related deaths". Salpeter 2006 only considered trials that compared long-acting beta 2 -agonists with placebo, and the review was not able to include 28 trials in the primary analysis (including nearly 6000 patients) because information was not provided for asthma-related deaths.
Currently there are two long-acting beta 2 -agonists available, salmeterol and formoterol (also known as eformoterol). These two drugs are known to have differences in speed of onset and receptor activity, and are used in different ways. Salmeterol has a slower onset of action than formoterol and is not used as relief medication, whereas formoterol can be used for maintenance and relief of symptoms. Not all beta 2 -agonists carry the same risks, as pointed out in the book entitled 'The Fenoterol Story' (Pearce 2007). Appendix 2 discusses the possible mechanisms of increased asthma mortality with beta-agonists in more detail. There is a need to systematically review all the available data from controlled trials that have compared patients randomised to regular formoterol or regular salmeterol without randomised inhaled corticosteroids, although it is likely that such patients in trials would already be prescribed background treatment with inhaled corticosteroids. We considered all SAEs (fatal and non-fatal), whether or not these were deemed by the investigators to be related to trial medication.
O B J E C T I V E S
To assess the risk of mortality and non-fatal SAEs in trials which have randomised patients with chronic asthma to regular formoterol versus regular salmeterol.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials (RCTs) of parallel design, with or without blinding, in which patients with chronic asthma were randomly assigned to regular treatment with formoterol versus salmeterol. We excluded studies on acute asthma and exerciseinduced bronchospasm.
Types of participants
We included patients with a clinical diagnosis of asthma of any age group, unrestricted by disease severity, previous or current treatment.
Types of interventions
We included trials that randomised patients to receive inhaled formoterol versus salmeterol given regularly for a period of at least 12 weeks, but not randomised with inhaled corticosteroids. We excluded studies that used adjustable maintenance dosing and single inhaler therapy (for maintenance and relief of symptoms).
Types of outcome measures
Outcomes were not subdivided according to whether the trial investigators considered them to be related to trial medication.
Primary outcomes
1. All-cause mortality 2. All-cause non-fatal SAEs
Secondary outcomes
1. Asthma-related mortality 2. Asthma-related non-fatal SAEs 3. Cardiovascular-related mortality An illustrative example of the definition of SAEs used in trials by GlaxoSmithKline is shown in Appendix 3
Search methods for identification of studies Electronic searches
We identified trials using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see Appendix 4 for further details). We searched all records in the Specialised Register coded as 'asthma' using the following terms: (salmeterol or serevent) AND (formoterol or eformoterol or oxis or foradil) AND (serious or safety or surveillance or mortality or death or intubat* or adverse or toxicity or complications or tolerability) In addition we carried out a further search just using the terms: (salmeterol or serevent) AND (formoterol or eformoterol or oxis or foradil). We conducted the latest searches in January 2012.
Searching other resources
We checked reference lists of all primary studies and review articles for additional references. We also checked websites of clinical trial registers for unpublished trial data and checked FDA submissions in relation to formoterol.
Data collection and analysis
Selection of studies
Both review authors independently assessed studies identified in the literature searches by examining titles, abstract and keywords fields. We obtained studies that potentially fulfilled the inclusion criteria in full text. We independently assessed these full-text trial reports for inclusion. No disagreements occurred over the inclusion or exclusion of studies.
Data extraction and management
CJC extracted data using a prepared checklist and entered them into RevMan 5 (RevMan 2011). TL independently extracted the results. Data included characteristics of included studies (methods, participants, interventions, outcomes) and results of the included studies. We contacted authors and sponsors of included studies for unpublished adverse event data, and searched manufacturers' websites for further details of adverse events. We also searched FDA submissions. We recorded all-cause SAEs (fatal and nonfatal) and, in view of the difficulty in deciding whether events are asthma-related, we noted details of the cause of death and SAEs where they were available. We also sought the definition of SAEs.
Assessment of risk of bias in included studies
CJC assessed the included studies for bias protection (including sequence generation for randomisation, allocation concealment, blinding of participants and assessors, loss to follow-up, completeness of outcome assessment and other possible sources of bias), and this was independently verified by TL.
Unit of analysis issues
We extracted data using the number of participants who suffered one or more SAEs, in order to avoid double-counting events from the same participant.
Assessment of heterogeneity
We assessed heterogeneity in the pooled odds ratio using the I 2 statistic in RevMan 5 to indicate how much of the total heterogeneity found was between, rather than within, studies.
Data synthesis
The outcomes of this review were dichotomous and we recorded the number of participants with each outcome event by allocated treated group. We calculated pooled odds ratio (OR) and risk difference (RD). The Peto OR has advantages when events are rare, as no adjustment for zero cells is required. This property was found in previous reviews to be more important than potential problems with unbalanced treatment arms and large effect sizes, and we therefore calculated the results for SAEs in RevMan 5 using the Peto method with the Mantel-Haenszel method for sensitivity analysis. We could not use funnel plots to assess publication bias, as very few trials were identified.
Subgroup analysis and investigation of heterogeneity
We planned to compare subgroups using tests for interaction (Altman 2003) . However, events were too sparse to allow a meaningful comparison of the results in adults and children, and background non-randomised use of inhaled corticosteroids was used in all studies, so subgroup analysis by background inhaled corticosteroid use was not possible.
Sensitivity analysis
We performed sensitivity analysis to assess the impact of the method used to combine the study events (risk difference, Peto OR and Mantel-Haenszel OR). The degree of bias protection in the study designs was part of planned sensitivity analysis, but all the studies were of open design and reporting of sequence generation and allocation concealment was poor.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
Results of the search
We carried out the original search in January 2009 and identified 40 references (155 references without the adverse event filter). We identified three studies for inclusion (Condemi 2001; Everden 2004; Vervloet 1998) from the shorter list of references. When this was rechecked against the unfiltered list we identified one further study (Gabbay 1998), which had been published in abstract form only in 1998, and found four further references related to the three included studies. We identified 13 further studies for possible inclusion, but we excluded them after more detailed inspection (see Characteristics of excluded studies). We carried out an updated search in January 2012 but there were no new studies included.
Included studies
Of the four included studies, three enrolled a combined total of 1137 adults (Condemi 2001; Gabbay 1998; Vervloet 1998), and one enrolled 156 children (Everden 2004). Vervloet 1998 included adults with reversible airways obstruction, and whilst they did not seek to exclude participants with chronic obstructive pulmonary disease (COPD), they indicated that most participants suffered from asthma, so both review authors independently decided that this study should be included. All the studies compared a twice daily dose of formoterol 12 µg with twice daily salmeterol 50 µg. 
Risk of bias in included studies Allocation
Few details were available in relation to sequence generation or allocation concealment. As all the studies were sponsored by Novartis or AstraZeneca it is likely that they were adequately protected from the risk of selection bias.
Blinding
All the studies were open-label in design, so unprotected against performance bias. We remain uncertain as to the impact of this on the outcomes primarily of interest to this review.
Incomplete outcome data
The adult studies had low dropout rates, but the study in children had higher dropout rates and these were not balanced between the trial arms. Thirty-three out of 127 children discontinued the study (formoterol 21, salmeterol 12). All children who took at least one dose of medication were included in the analysis.
Selective reporting
No serious adverse event data were published in the abstract of Gabbay 1998, and no full publication has been identified after correspondence with the author, who was unable to offer further information. Vervloet 1998 also included information on all adverse events only, but no separate data on SAEs. Novartis have been able to provide data on file for SAEs in both of these studies. An overview of the risks of bias is shown in Figure 1 . 
Effects of interventions
See: Summary of findings for the main comparison Regular formoterol compared to regular salmeterol for chronic asthma: serious adverse events All studies have contributed serious adverse event data to this review: Condemi 2001 (528 adults studied for six months) and Everden 2004 (156 children studies for three months) from published papers and Gabbay 1998 (127 adults for three months) and Vervloet 1998 (482 adults for six months) from data on file at Novartis.
All-cause mortality
No deaths were reported in 528 adults in Condemi 2001. Novartis have confirmed that there were no deaths in Gabbay 1998, and in Vervloet 1998 there was one participant who died of heart disease following coronary surgery in the salmeterol group. AstraZeneca have confirmed that there were no deaths in the 156 children in Everden 2004. There are insufficient data to draw any firm conclusions in relation to mortality, but using the pooled risk difference (RD) to combine the results of studies, the overall risk difference in adults (RD -0.00; 95% confidence interval (CI) -0.01 to 0.01) and in children (RD 0.00; 95% CI -0.02 to 0.02) is as shown in Figure 2 . This indicates that the maximum absolute difference between treatments in adults who have been studied is one percentage point either way, and in children is two percentage points either way. This range of uncertainty needs to be considered in the context of a mortality rate of 0.05% found in studies on formoterol alone (Cates 2008a). Gabbay 1998 recorded only one patient with a serious adverse event (an asthma exacerbation); the patient was not included in the safety analysis for this trial as it could not be confirmed that any of the study drug (salmeterol) had been taken. The Peto odds ratio (OR) comparing formoterol to salmeterol was not significantly different between groups (Peto OR 0.77; 95% CI 0.46 to 1.28 (Figure 3) ), nor was the risk difference (RD -0.01; 95% CI -0.04 to 0.01). Over the six-month period for adults that contributed to this analysis the percentages of adults with SAEs were formoterol 5.1% and salmeterol 6.4%. We performed a sensitivity analysis to assess the addition of the patient from Gabbay 1998 and this gave very similar results (Peto OR 0.75; 95% CI 0.45 to 1.24). The OR was also virtually unchanged using Mantel-Haenszel random (OR 0.77; 95% CI 0.46 to 1.29) or fixed method (OR 0.77; 95% CI 0.46 to 1.28).
Children
Everden 2004 reported one out of 80 children experiencing SAEs on formoterol and one out of 76 children on salmeterol. Over the three-month period the percentages of children with SAEs were formoterol 1.3% and salmeterol 1.3%. The Peto OR was not significantly different between groups (Peto OR 0.96; 95% CI 0.06 to 15.52), nor was the risk difference (RD -0.0005; 95% CI -0.04 to 0.04).
Asthma-related SAEs
Adults
Of all the SAEs reported in Condemi 2001, two adults on formoterol and three adults on salmeterol were classified as having events related to asthma. In Vervloet 1998 there were four adults in each group with events related to asthma. Again there is no significant difference between the treatment groups (Peto OR 0.86; 95% CI 0.29 to 2.57 (Figure 4) ). Sensitivity analysis to include the additional patient in Gabbay 1998 again gave very similar pooled results (Peto OR 0.76; 95% CI 0.26 to 2.17).
Children
Neither of the SAEs in children in Everden 2004 were asthmarelated.
D I S C U S S I O N Summary of main results
We identified only three studies involving adults (N = 1116) and one study in children (N = 155) for inclusion in this review. Serious adverse events (SAEs) were rare, especially those related to asthma. Only one non-asthma-related death occurred. No significant differences in SAEs were found between regular formoterol and regular salmeterol in adults or children with asthma. All of the participants enrolled were taking inhaled corticosteroids at baseline.
Overall completeness and applicability of evidence
All of the studies enrolled patients who were already taking inhaled corticosteroids. Therefore it has not been possible to assess the relative safety of formoterol and salmeterol in patients who were not prescribed background inhaled corticosteroids, but this is no longer considered acceptable practice.
Quality of the evidence
No double-blind trials have been carried out comparing regular formoterol with regular salmeterol. The open studies included in this review could have been influenced by the fact that the participants and investigators were aware of the assigned treatment for each patient, especially in studies sponsored by the companies marketing one of the comparator medications.
Potential biases in the review process
Data on SAEs have been obtained for all of the included studies.
Agreements and disagreements with other studies or reviews
Our two previous reviews (Cates 2008; Cates 2008a) indicated an increase in all-cause SAEs when both regular formoterol and regular salmeterol were compared with placebo. It would require very large numbers of patients in head-to-head comparison trials to determine whether there is any difference in SAEs between regular formoterol and salmeterol, and it is perhaps not surprising that it has not been possible to draw conclusions from this review, as the number of participants in the included trials is relatively small.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Four unblinded studies have been identified comparing regular formoterol to regular salmeterol. SAEs were infrequent and consequently too few patients have been studied to allow firm conclusions to be drawn. Asthma-related SAEs were rare and there were no reported asthma-related deaths.
Implications for research
In order to compare the safety of regular formoterol and regular salmeterol, much larger surveillance studies would need to be carried out. Ideally these should be double-blind, double-dummy, parallel-group studies.
A further review compares regular formoterol and salmeterol when randomised together with additional inhaled corticosteroids (Cates 2011).
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Condemi 2001
Methods Inclusion criteria: outpatients aged 6 to 17 years, with a clinical diagnosis of moderate, persistent asthma. Had to have been receiving ICS for asthma at a constant dose for at least 4 weeks prior to enrolment, currently using inhaled short-acting beta 2 -agonists for relief of asthma symptoms, and have had asthma symptoms occurring on at least 3 days or nights out of the past 7 days prior to enrolment. For randomisation, needed to have continued to experience asthma symptoms and to have used at least 7 actuations of short-acting b2-agonists in the last 7 days or nights for relief of asthma symptoms Exclusion criteria: PEF predicted less than 50%, asthma symptoms requiring immediate treatment, significant concurrent disease or health problems, or a requirement for additional medication (e.g. ß-blocker therapy, nebulised therapy, oral steroids or oral short-acting beta 2 -agonists) which may have interfered with the evaluation of the study drug Heterogeneity: Chi 2 = 1.24, df = 2 (P = 0.54); I 2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26) Adapted from Hanania 2002. The authors acknowledge that it is difficult to determine the intrinsic efficacy of salmeterol given its high lipophilicity.
A D D I T I O N A L T A B L E S
A P P E N D I C E S Appendix 1. Pharmacology of beta 2 -agonists
Beta 2 -agonists are thought to cause bronchodilation primarily through binding beta 2 -adrenoceptors on airways smooth muscle (ASM), with subsequent activation of both membrane-bound potassium channels and a signalling cascade involving enzyme activation and changes in intracellular calcium levels following a rise in cyclic adenosine monophosphate (cAMP) (Barnes 1993). However, beta 2 -adrenoceptors are also expressed on a wide range of cell types where beta 2 -agonists may have a clinically significant effect including airway epithelium (Morrison 1993), mast cells, post capillary venules, sensory and cholinergic nerves and dendritic cells (Anderson  2006) . Beta 2 -agonists will also cross-react to some extent with other beta-adrenoceptors including beta 1 -adrenoceptors on the heart. The in vivo effect of any beta 2 -agonist will depend on a number of factors relating to both the drug and the patient. The degree to which a drug binds to one receptor over another is known as selectivity, which can be defined as absolute binding ratios to different receptors in vitro, whilst functional selectivity is measured from downstream effects of drugs in different tissue types in vitro or in vivo. All of the beta 2 -agonists described thus far are more beta 2 selective than their predecessor isoprenaline in vitro. However, because attempts to differentiate selectivity between the newer agents are confounded by so many factors, it is difficult to draw conclusions about in vitro selectivity studies and probably best to concentrate on specific adverse side effects in human subjects at doses which cause the same degree of bronchoconstriction. The potency of a drug refers to the concentration that achieves half the maximal receptor activation of which that drug is capable but it is not very important clinically as for each drug, manufacturers will alter the dose to try to achieve a therapeutic ratio of desired to undesired effects. In contrast efficacy refers to the ability of a drug to activate its receptor independent of drug concentration. Drugs that fully activate a receptor are known as full agonists and those that partially activate a receptor are known as partial agonists. Efficacy also is very much dependent on the system in which it is being tested and is affected by factors including the number of receptors available and the presence of other agonists and antagonists. Thus whilst salmeterol acts as a partial agonist in vitro it causes a similar degree of bronchodilation to the strong agonist formoterol in stable asthmatic patients (van Noord 1996), presumably because there are an abundance of well-coupled beta 2 -adrenoceptors available with few downstream antagonising signals. In contrast, with repetitive dosing formoterol is significantly better than salmeterol at preventing methacholineinduced bronchoconstriction (Palmqvist 1999). These differences have led to attempts to define the "intrinsic efficacy" of a drug independent of tissue conditions (Hanania 2002), as shown in Table 1 . The clinical significance of intrinsic efficacy remains unclear.
Appendix 2. Possible mechanisms of increased asthma mortality with beta-agonists Direct toxicity
This hypothesis states that direct adverse effects of beta 2 -agonists are responsible for an associated increase in mortality and most research in the area has concentrated on effects detrimental to the heart. Whilst it is often assumed that cardiac side effects of beta 2 -agonists are due to cross-reactivity with beta 1 -adrenoceptors (i.e. poor selectivity), it is worth noting that human myocardium also contains an abundance of beta 2 -adrenoceptors capable of triggering positive chronotropic and inotropic responses (Lipworth 1992). Indeed, there is good evidence that cardiovascular side effects of isoprenaline (Arnold 1985) and other beta 2 -agonists including salbutamol (Hall 1989) are mediated predominantly via cardiac beta 2 -adrenoceptors thus making the concept of in vitro selectivity less relevant.
Generalised beta 2 -adrenoceptor activation can also cause hypokalaemia (Brown 1983) and it has been proposed that, through these and other actions beta 2 -agonists may predispose to life-threatening dysrhythmias or cause other adverse cardiac effects. During the 1960s epidemic most deaths occurred in patients with severe asthma and it was originally assumed that asthma and its sequelae, including hypoxia, were the primary cause of death. However, mucus plugging and hypoxia does not preclude a cardiac event as the final cause of death, and one might expect those with severe asthma to take more doses of a prescribed inhaler. As noted by Speizer and Doll most deaths in the 1960s were in the 10 to 19 age group and "at these ages children have begun to act independently and may be particularly prone to misuse a self-administered form of treatment" (Speizer 1968). If toxicity were related to increasing doses of beta 2 -agonists one might expect most deaths to occur in hospital where high doses are typically used and this was not the case. One possible explanation for this anomaly was provided by animal experiments in which large doses of isoprenaline caused little ill effect in anaesthetised dogs with normal arterial oxygenation whereas much smaller doses caused fatal cardiac depression and asystole (although no obvious dysrhythmia) when hypoxic (Collins 1969; McDevitt 1974) . It has been hypothesised therefore that such events would be less likely in hospital where supplemental oxygen is routinely given. The clinical relevance of these studies remains unclear although there is some evidence of a synergistic effect between hypoxia and salbutamol use in asthmatic patients in reducing total peripheral vascular resistance (Burggraaf 2001) -another beta 2 mediated effect which could be detrimental to the heart during an acute asthma attack through a reduction in diastolic blood pressure. Other potential mechanisms of isoprenaline toxicity include a potential increase in mucous plugging and worsening of ventilation perfusion mismatch despite bronchodilation (Pearce 1990).
Further concerns about a possible toxic effect of beta 2 -agonists were raised during the New Zealand epidemic in the 1970s. In 1981 Wilson et al, who first reported the epidemic, reviewed 22 fatal cases of asthma and noted "In 16 patients death was seen to be sudden and unexpected. Although all were experiencing respiratory distress, most were not cyanosed and the precipitate nature of their death suggested a cardiac event, such as an arrest, inappropriate to the severity of their respiratory problem" (Wilson 1981). In humans, fenoterol causes significantly greater chronotropic, inotropic and electrocardiographic side effects than salbutamol in asthmatic patients (Wong 1990). Interestingly, across the same parameters fenoterol also causes more side effects than isoprenaline (Burgess 1991).
In patients with mild asthma and without a bronchoconstrictor challenge, salmeterol and salbutamol cause a similar degree of near maximal bronchodilation at low doses (Bennett 1994). However, whilst as a one-off dose salbutamol is typically used at two to four times the concentration of salmeterol, the dose equivalences for salmeterol versus salbutamol in increasing heart rate and decreasing potassium concentration and diastolic blood pressure were 17.7, 7.8 and 7.6 respectively (i.e. salmeterol had a greater effect across all parameters). Given the lower intrinsic efficacy of salmeterol (Table 1) , these results highlight the importance of in vivo factors; one possible explanation for the difference is the increased lipophilicity of salmeterol compared to salbutamol contributing to higher systemic absorption (Bennett 1994). When comparing increasing actuations of standard doses of formoterol and salmeterol inhalers in stable asthmatic patients, relatively similar cardiovascular effects are seen at lower doses (Guhan 2000) . However, at the highest doses (above those recommended by the manufacturers) there were trends towards an increase in systolic blood pressure with formoterol; in comparison there was a trend towards a decrease in diastolic blood pressure and an increase in QTc interval with salmeterol although no statistical analysis of the difference was performed. In contrast in asthmatic patients with methacholine-induced bronchoconstriction there was no significant difference between salmeterol and formoterol in causing increased heart rate and QTc interval although formoterol caused significantly greater bronchodilation and hypokalaemia (Palmqvist 1999). Whilst there is good evidence of cardiovascular and metabolic side effects with increasing doses of beta 2 -agonists, it is a little difficult to envisage serious adverse effects of this nature when using long-acting beta 2 -agonists (LABAs) at manufacturer-recommended preventative doses. However, it is possible that some patients choose to use repeated doses of LABAs during exacerbations.
Tolerance
In this setting, the term tolerance refers to an impaired response to beta 2 -agonists in patients who have been using regular beta 2 -agonist treatment previously (Haney 2006). Tolerance is likely to result from a combination of reduced receptor numbers secondary to receptor internalisation and reduced production and also uncoupling of receptors to downstream signalling pathways following repeated activation (Barnes 1995). This phenomenon is likely to explain the beneficial reduction in systemic side effects seen with regular use of beta 2 -agonists including salbutamol after one to two weeks (Lipworth 1989). However, the same effect on beta 2 -adrenoceptors in the lung might be expected to produce a diminished response to the bronchodilating activity of beta 2 -agonists following regular use. In patients with stable asthma, whilst there is some evidence of tolerance to both salbutamol (Nelson 1977) At first glance the toxicity and tolerance hypotheses might appear incompatible as systemic and cardiovascular tolerance ought to protect against toxicity in the acute setting and there is good evidence that such tolerance occurs in stable asthmatic patients (Lipworth 1989). However, whilst this study showed that changes in heart rate and potassium levels were blunted by previous beta 2 -agonist use, they were not abolished; furthermore, at the doses studied these side effects appear to follow an exponential pattern (Lipworth 1989). In contrast, in the presence of bronchoconstrictor stimuli the bronchodilator response to beta 2 -agonists follows a flatter curve (Hancox 1999; Wong 1990) and as previously discussed this curve is shifted downwards by previous beta 2 -agonist exposure (Hancox 1999). Thus, it is theoretically possible that in the setting of an acute asthmatic attack and strong bronchoconstricting stimuli, bronchodilator tolerance could lead to repetitive beta 2 -agonist use and ultimately more systemic side effects than would otherwise have occurred. Of course, other sequelae of inadequate bronchodilation including airway obstruction will be detrimental in this setting. Whilst the tolerance hypothesis is often cited as contributing towards the asthma mortality epidemics it is difficult to argue that reduced efficacy of a drug can cause increased mortality relative to a time when that drug was not used at all. However, tolerance to the bronchodilating effect of endogenous circulating adrenaline is theoretically possible and there is also evidence of rebound bronchoconstriction when stopping fenoterol (Sears 1990), which may be detrimental. Furthermore, it appears that regular salbutamol treatment can actually increase airway responsiveness to allergen (Cockcroft 1993) a potentially important effect that could form a variant of the toxicity hypothesis. Differences between beta 2 -agonists in this regard are unclear, but the combination of rebound hyper responsiveness and tolerance of the bronchodilator effect with regular beta 2 -agonist exposure has been recently advocated as a possible mechanism to explain the association between beta 2 -agonists and asthma mortality (Hancox 2006a).
Other explanations
Confounding by severity
Historically, this hypothesis has been used extensively to try to explain the association between mortality and the use of fenoterol during the 1970s New Zealand epidemic (see Pearce 2007) and is still quoted today. The hypothesis essentially relies on the supposition that patients with more severe asthma are more likely to take either higher doses of beta 2 -agonists or a particular beta 2 -agonist (such as fenoterol) thereby explaining the association. This hypothesis was carefully ruled out in the three case-control studies by comparing the association between fenoterol and mortality in patients with varying severity of disease (Crane 1989; Grainger 1991; Pearce 1990). Furthermore, the hypothesis cannot explain the overall increase in mortality in the 1960s and 1970s nor can it explain any significant increase in mortality (whether taking inhaled steroids or not) from randomised controlled trial data.
The delay hypothesis
This hypothesis accepts that beta 2 -agonists or a particular beta 2 -agonist cause an increased risk of mortality but indirectly by causing patients to delay before getting medical help and further treatments including high-dose steroids and oxygen. There is evidence that both salmeterol and formoterol can reduce awareness of worsening underlying inflammation (Bijl-Hofland 2001; McIvor 1998). It is difficult to rule out the delay hypothesis in either explaining or contributing towards both the asthma mortality epidemics and an association with regular use of LABAs. There is evidence that beta 2 -agonists with higher intrinsic efficacy are more effective at relieving bronchoconstriction in the acute setting (Hanania 2007) and could paradoxically cause patients to delay seeking medical help for longer. For the delay hypothesis to explain the increase in mortality during the 1960s and 1970s one has to imply that hospital treatment of asthma when mortality rates were low during the earlier years of the 20 th century was effective. It is difficult to say exactly how effective such treatment is likely to have been.
Reduced corticosteroid treatment
A slight but significant variation of the delay hypothesis suggests that patients who have separate beta 2 -agonists and corticosteroid inhalers may choose to take less corticosteroid because of better symptom control from the inhaled beta 2 -agonists and it is reduced corticosteroid treatment that contributes to a rise in mortality. It is rather difficult to see how this hypothesis explains the epidemics of asthma deaths in the 1960s and 1970s relative to the 1920s and 30s (Figure 5 ), given that corticosteroids were not used for the treatment of asthma in the earlier decades. If this hypothesis were to explain increased mortality from more recent randomised controlled trial data one would not expect to see an increase in mortality in those taking LABAs alone. 7. groups.ab,ti. 8. or/1-7 9. Animals/ 10. Humans/ 11. 9 not (9 and 10) 12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
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